ELIC.ST
Elicera Therapeutics AB (publ) [ELIC.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ELIC.ST Stock Summary
Top 10 Correlated ETFs
ELIC.ST
Top 10 Correlated Stocks
ELIC.ST
In the News
ELIC.ST Financial details
Company Rating
-
Market Cap
24.13M
Income
-16.4M
Revenue
3.18M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
2
Optionable
No
Shortable
Yes
Earnings
13 Feb 2024
P/E
-6.69
Forward P/E
-
PEG
4.14
P/S
-
P/B
4.9
P/C
-
P/FCF
-8.03
Quick Ratio
3.7
Current Ratio
4.02
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.83
EPS next Y
-
EPS next Q
-
EPS this Y
-16.16%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-7.69%
-
-
-
-
SMA20
56.28%
SMA50
35.92%
SMA100
120.57%
Inst Own
-
Inst Trans
-
ROA
-55%
ROE
-56%
ROC
-0.75%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.0-7.24
52W High
-39.43%
52W Low
+324%
RSI
72.84
Rel Volume
1.59
Avg Volume
96.23K
Volume
153.46K
Perf Week
29.66%
Perf Month
69.6%
Perf Quarter
126.74%
Perf Half Y
109.9%
-
-
-
-
Beta
-0.594
-
-
Volatility
0.45%, 0.65%
Prev Close
-4.07%
Price
4.24
Change
-5.57%
Company Profile
- Volume Average 96.23K
- Market Capitalization 24.13M
- Employee 2
- CEO Mr. Jamal El-Mosleh M.Sc.
- Headquarters Gothenburg,SE
- IPO Date 2021-06-11
-
Website
https://www.elicera.com 
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate for neuroendocrine tumors indications; ELC-201, a preclinical drug candidate; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a preclinical drug candidate glioblastoma multiforme (brain tumor) indications. It also develops iTANK, a technology platform used to optimize the effect of all CAR T-cell therapies under the development and activate killer T-cells against cancer. The company was founded in 2014 and is based in Göteborg, Sweden.
